<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><!-- generator="wordpress/2.2" --><rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">

<channel>
	<title>SEBIO News</title>
	<link>http://news.sebio.org</link>
	<description>Just another WordPress weblog</description>
	<pubDate>Mon, 02 Nov 2009 23:17:20 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2</generator>
	<language>en</language>
			<atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" href="http://feeds.feedburner.com/SebioNews" type="application/rss+xml" /><feedburner:emailServiceId xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0">SebioNews</feedburner:emailServiceId><feedburner:feedburnerHostname xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0">http://feedburner.google.com</feedburner:feedburnerHostname><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com" /><item>
		<title>Alimera Sciences Refiles for IPO</title>
		<link>http://news.sebio.org/2009/11/02/alimera-sciences-refiles-for-ipo/</link>
		<comments>http://news.sebio.org/2009/11/02/alimera-sciences-refiles-for-ipo/#comments</comments>
		<pubDate>Mon, 02 Nov 2009 23:17:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Other Regional News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/11/02/alimera-sciences-refiles-for-ipo/</guid>
		<description><![CDATA[Atlanta, GA - Alimera Sciences Inc., an ophthalmic pharmaceutical firm, has refiled for an $80 million initial public offering of stock. The company withdrew registration for a $75 million IPO earlier this year due to market conditions at the time.
]]></description>
			<content:encoded><![CDATA[<p>Atlanta, GA - Alimera Sciences Inc., an ophthalmic pharmaceutical firm, has refiled for an $80 million initial public offering of stock. The company withdrew registration for a $75 million IPO earlier this year due to market conditions at the time.  <a href="http://news.sebio.org/2009/11/02/alimera-sciences-refiles-for-ipo/#more-269" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/11/02/alimera-sciences-refiles-for-ipo/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Aldagen Refiles for IPO, Raises $7.3M of $10M in Debt, Warrants</title>
		<link>http://news.sebio.org/2009/10/29/aldagen-refiles-for-ipo-raises-73m-of-10m-in-debt-warrants/</link>
		<comments>http://news.sebio.org/2009/10/29/aldagen-refiles-for-ipo-raises-73m-of-10m-in-debt-warrants/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 20:42:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Other Regional News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/29/aldagen-refiles-for-ipo-raises-73m-of-10m-in-debt-warrants/</guid>
		<description><![CDATA[Durham, NC - Stem cell company Aldagen Inc. has refiled to go public and has raised $7.3 million of a targeted $10 million debt and warrants raise, according to SEC filings. The company hopes to raise as much as $80.5 million selling stock on Nasdaq under the symbol &#8220;ALDH.&#8221;
]]></description>
			<content:encoded><![CDATA[<p>Durham, NC - Stem cell company Aldagen Inc. has refiled to go public and has raised $7.3 million of a targeted $10 million debt and warrants raise, according to SEC filings. The company hopes to raise as much as $80.5 million selling stock on Nasdaq under the symbol &#8220;ALDH.&#8221;  <a href="http://news.sebio.org/2009/10/29/aldagen-refiles-for-ipo-raises-73m-of-10m-in-debt-warrants/#more-268" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/29/aldagen-refiles-for-ipo-raises-73m-of-10m-in-debt-warrants/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Georgia-based Biotech Halscion Collects $6M of $35.5M Raise</title>
		<link>http://news.sebio.org/2009/10/29/georgia-based-biotech-halscion-collects-6m-of-355m-raise/</link>
		<comments>http://news.sebio.org/2009/10/29/georgia-based-biotech-halscion-collects-6m-of-355m-raise/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 20:38:16 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/29/georgia-based-biotech-halscion-collects-6m-of-355m-raise/</guid>
		<description><![CDATA[Duluth, GA - Halscion Inc., a biotech company developing a device to reduce the appearance of scares from surgical wounds, has raised $6 million of a targeted $35.5 million round, according to a regulatory filing.
]]></description>
			<content:encoded><![CDATA[<p>Duluth, GA - Halscion Inc., a biotech company developing a device to reduce the appearance of scares from surgical wounds, has raised $6 million of a targeted $35.5 million round, according to a regulatory filing.  <a href="http://news.sebio.org/2009/10/29/georgia-based-biotech-halscion-collects-6m-of-355m-raise/#more-267" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/29/georgia-based-biotech-halscion-collects-6m-of-355m-raise/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Metabolon Adds $6M to C Round for $12.3M Total</title>
		<link>http://news.sebio.org/2009/10/27/metabolon-adds-6m-to-c-round-for-123m-total/</link>
		<comments>http://news.sebio.org/2009/10/27/metabolon-adds-6m-to-c-round-for-123m-total/#comments</comments>
		<pubDate>Tue, 27 Oct 2009 16:25:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/27/metabolon-adds-6m-to-c-round-for-123m-total/</guid>
		<description><![CDATA[Durham, NC - Metabolon Inc., a company selling biomarker discovery and analysis services, has closed on an additional $6 million Series C funding, bringing its C round total to $12.3 million. New investors were Syngenta Ventures, the corporate venture capital subsidiary of Syngenta, and Fletcher Spaght Ventures.
]]></description>
			<content:encoded><![CDATA[<p>Durham, NC - Metabolon Inc., a company selling biomarker discovery and analysis services, has closed on an additional $6 million Series C funding, bringing its C round total to $12.3 million. New investors were Syngenta Ventures, the corporate venture capital subsidiary of Syngenta, and Fletcher Spaght Ventures.  <a href="http://news.sebio.org/2009/10/27/metabolon-adds-6m-to-c-round-for-123m-total/#more-265" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/27/metabolon-adds-6m-to-c-round-for-123m-total/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Altor Bioscience Closes on First $1.2M of C Round Series</title>
		<link>http://news.sebio.org/2009/10/26/altor-bioscience-closes-on-first-12m-of-c-round-series/</link>
		<comments>http://news.sebio.org/2009/10/26/altor-bioscience-closes-on-first-12m-of-c-round-series/#comments</comments>
		<pubDate>Mon, 26 Oct 2009 16:29:47 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/26/altor-bioscience-closes-on-first-12m-of-c-round-series/</guid>
		<description><![CDATA[Miramar, FL - Altor Bioscience, a company developing treatments that target drugs directly at a tumor or virus, has closed on $1.2 million as part of a series of C1 round investments. Sanderling Ventures, which led the company’s B round, and private investors participated.
]]></description>
			<content:encoded><![CDATA[<p>Miramar, FL - Altor Bioscience, a company developing treatments that target drugs directly at a tumor or virus, has closed on $1.2 million as part of a series of C1 round investments. Sanderling Ventures, which led the company’s B round, and private investors participated.  <a href="http://news.sebio.org/2009/10/26/altor-bioscience-closes-on-first-12m-of-c-round-series/#more-266" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/26/altor-bioscience-closes-on-first-12m-of-c-round-series/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Inhibitex Raises $23M in Private Placement</title>
		<link>http://news.sebio.org/2009/10/23/inhibitex-raises-23m-in-private-placement/</link>
		<comments>http://news.sebio.org/2009/10/23/inhibitex-raises-23m-in-private-placement/#comments</comments>
		<pubDate>Fri, 23 Oct 2009 18:17:58 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/23/inhibitex-raises-23m-in-private-placement/</guid>
		<description><![CDATA[Atlanta, GA - Inhibitex Inc. (Nasdaq: INHX) has entered into definitive purchase agreements with institutional investors for the sale of approximately $23 million of its common stock, and warrants to purchase common stock, in a private placement.
]]></description>
			<content:encoded><![CDATA[<p>Atlanta, GA - Inhibitex Inc. (Nasdaq: INHX) has entered into definitive purchase agreements with institutional investors for the sale of approximately $23 million of its common stock, and warrants to purchase common stock, in a private placement.  <a href="http://news.sebio.org/2009/10/23/inhibitex-raises-23m-in-private-placement/#more-262" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/23/inhibitex-raises-23m-in-private-placement/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Keraderm Nabs $2.5M Funding</title>
		<link>http://news.sebio.org/2009/10/23/keraderm-nabs-25m-funding/</link>
		<comments>http://news.sebio.org/2009/10/23/keraderm-nabs-25m-funding/#comments</comments>
		<pubDate>Fri, 23 Oct 2009 18:14:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/23/keraderm-nabs-25m-funding/</guid>
		<description><![CDATA[Blacksburg, VA - Keraderm Corp., a company starting clinical trials of its technology to use phototherapy to treat nail and skin infections, has raised a $2.5 million first round from NewVa Capital Partners.
]]></description>
			<content:encoded><![CDATA[<p>Blacksburg, VA - Keraderm Corp., a company starting clinical trials of its technology to use phototherapy to treat nail and skin infections, has raised a $2.5 million first round from NewVa Capital Partners.  <a href="http://news.sebio.org/2009/10/23/keraderm-nabs-25m-funding/#more-261" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/23/keraderm-nabs-25m-funding/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Envoy Therapeutics Nabs $8M</title>
		<link>http://news.sebio.org/2009/10/15/envoy-therapeutics-nabs-8m/</link>
		<comments>http://news.sebio.org/2009/10/15/envoy-therapeutics-nabs-8m/#comments</comments>
		<pubDate>Thu, 15 Oct 2009 18:28:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/15/envoy-therapeutics-nabs-8m/</guid>
		<description><![CDATA[Jupiter, FL - Envoy Therapeutics, a recently founded company focused on new treatments for neuological and psychiatric diseases, has raised an $8 million first round led by 5AM Ventures with Takea Research Investment and Roche Venture Fund participating.
]]></description>
			<content:encoded><![CDATA[<p>Jupiter, FL - Envoy Therapeutics, a recently founded company focused on new treatments for neuological and psychiatric diseases, has raised an $8 million first round led by 5AM Ventures with Takea Research Investment and Roche Venture Fund participating.  <a href="http://news.sebio.org/2009/10/15/envoy-therapeutics-nabs-8m/#more-260" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/15/envoy-therapeutics-nabs-8m/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Top Life Science Companies in the Southeast Announced</title>
		<link>http://news.sebio.org/2009/10/08/top-life-science-companies-in-the-southeast-announced/</link>
		<comments>http://news.sebio.org/2009/10/08/top-life-science-companies-in-the-southeast-announced/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 20:31:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[SEBIO News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/08/top-life-science-companies-in-the-southeast-announced/</guid>
		<description><![CDATA[Atlanta, GA - Southeast BIO (SEBIO) announces the selection of the best life sciences deals in the Southeast, as determined by a Selection Committee comprised of regional and national venture capitalists. These companies, both early- and later-stage, will participate in the upcoming SEBIO Investor Forum being held on December 3-4, 2009 at the Charleston Place [...]]]></description>
			<content:encoded><![CDATA[<p>Atlanta, GA - Southeast BIO (SEBIO) announces the selection of the best life sciences deals in the Southeast, as determined by a Selection Committee comprised of regional and national venture capitalists. These companies, both early- and later-stage, will participate in the upcoming SEBIO Investor Forum being held on December 3-4, 2009 at the Charleston Place Hotel in Charleston, South Carolina.  <a href="http://news.sebio.org/2009/10/08/top-life-science-companies-in-the-southeast-announced/#more-259" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/08/top-life-science-companies-in-the-southeast-announced/feed/</wfw:commentRss>
		</item>
		<item>
		<title>TransEnterix Raises $55M for Lapraroscopic Surgery Platform</title>
		<link>http://news.sebio.org/2009/10/07/transenterix-raises-55m-for-lapraroscopic-surgery-platform/</link>
		<comments>http://news.sebio.org/2009/10/07/transenterix-raises-55m-for-lapraroscopic-surgery-platform/#comments</comments>
		<pubDate>Wed, 07 Oct 2009 17:54:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[Regional Venture News]]></category>

		<guid isPermaLink="false">http://news.sebio.org/2009/10/07/transenterix-raises-55m-for-lapraroscopic-surgery-platform/</guid>
		<description><![CDATA[Research Triangle Park, NC - TransEnterix Inc. has secured $55 million in a second round of institutional financing led by Aisling Capital with new investors Intersouth Partners and Quaker BioVentures and existing investors SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisors participating. The company says the funding paves the way for [...]]]></description>
			<content:encoded><![CDATA[<p>Research Triangle Park, NC - TransEnterix Inc. has secured $55 million in a second round of institutional financing led by Aisling Capital with new investors Intersouth Partners and Quaker BioVentures and existing investors SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisors participating. The company says the funding paves the way for it to make and market its &#8220;revolutionary&#8221; laparoscopic surgical platform.  <a href="http://news.sebio.org/2009/10/07/transenterix-raises-55m-for-lapraroscopic-surgery-platform/#more-258" class="more-link">(more&#8230;)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://news.sebio.org/2009/10/07/transenterix-raises-55m-for-lapraroscopic-surgery-platform/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
